Choice of bronchodilator therapy in chronic obstructive pulmonary disease

Stephen Israel Rennard

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The majority of patients with chronic obstructive pulmonary disease may derive benefit from bronchodilator therapy, particularly those patients with severe disease. Currently, three classes of bronchodilator are available: anticholinergics, β2-adrenergic agonists and methylxanthines. Several factors should be considered when choosing a bronchodilator. Inhaled therapy is generally preferred over oral treatment as the inhaled route reduces systemic exposure to the drug, whereas oral therapy has the advantages of convenience and ease of use. The anticholinergics (e.g. ipratropium bromide) and β2-agonists (e.g. salbutamol) are used via the inhaled route and have approximately equivalent acute bronchodilator effects; they differ pharmacokinetically in onset of effect and duration of action and the anticholinergic may be superior in its long-term effects on lung function.

Original languageEnglish (US)
JournalRespirology
Volume2
Issue numberSUPPL. 1
StatePublished - Dec 1 1997

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Cholinergic Antagonists
Ipratropium
Adrenergic Agonists
Albuterol
Therapeutics
Lung
Pharmaceutical Preparations

Keywords

  • Anticholinergic
  • Bronchodilator
  • Chronic obstructive pulmonary disease
  • β-agonist

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Choice of bronchodilator therapy in chronic obstructive pulmonary disease. / Rennard, Stephen Israel.

In: Respirology, Vol. 2, No. SUPPL. 1, 01.12.1997.

Research output: Contribution to journalArticle

Rennard, Stephen Israel. / Choice of bronchodilator therapy in chronic obstructive pulmonary disease. In: Respirology. 1997 ; Vol. 2, No. SUPPL. 1.
@article{6109ac942888447d9e1289e774ae3679,
title = "Choice of bronchodilator therapy in chronic obstructive pulmonary disease",
abstract = "The majority of patients with chronic obstructive pulmonary disease may derive benefit from bronchodilator therapy, particularly those patients with severe disease. Currently, three classes of bronchodilator are available: anticholinergics, β2-adrenergic agonists and methylxanthines. Several factors should be considered when choosing a bronchodilator. Inhaled therapy is generally preferred over oral treatment as the inhaled route reduces systemic exposure to the drug, whereas oral therapy has the advantages of convenience and ease of use. The anticholinergics (e.g. ipratropium bromide) and β2-agonists (e.g. salbutamol) are used via the inhaled route and have approximately equivalent acute bronchodilator effects; they differ pharmacokinetically in onset of effect and duration of action and the anticholinergic may be superior in its long-term effects on lung function.",
keywords = "Anticholinergic, Bronchodilator, Chronic obstructive pulmonary disease, β-agonist",
author = "Rennard, {Stephen Israel}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Choice of bronchodilator therapy in chronic obstructive pulmonary disease

AU - Rennard, Stephen Israel

PY - 1997/12/1

Y1 - 1997/12/1

N2 - The majority of patients with chronic obstructive pulmonary disease may derive benefit from bronchodilator therapy, particularly those patients with severe disease. Currently, three classes of bronchodilator are available: anticholinergics, β2-adrenergic agonists and methylxanthines. Several factors should be considered when choosing a bronchodilator. Inhaled therapy is generally preferred over oral treatment as the inhaled route reduces systemic exposure to the drug, whereas oral therapy has the advantages of convenience and ease of use. The anticholinergics (e.g. ipratropium bromide) and β2-agonists (e.g. salbutamol) are used via the inhaled route and have approximately equivalent acute bronchodilator effects; they differ pharmacokinetically in onset of effect and duration of action and the anticholinergic may be superior in its long-term effects on lung function.

AB - The majority of patients with chronic obstructive pulmonary disease may derive benefit from bronchodilator therapy, particularly those patients with severe disease. Currently, three classes of bronchodilator are available: anticholinergics, β2-adrenergic agonists and methylxanthines. Several factors should be considered when choosing a bronchodilator. Inhaled therapy is generally preferred over oral treatment as the inhaled route reduces systemic exposure to the drug, whereas oral therapy has the advantages of convenience and ease of use. The anticholinergics (e.g. ipratropium bromide) and β2-agonists (e.g. salbutamol) are used via the inhaled route and have approximately equivalent acute bronchodilator effects; they differ pharmacokinetically in onset of effect and duration of action and the anticholinergic may be superior in its long-term effects on lung function.

KW - Anticholinergic

KW - Bronchodilator

KW - Chronic obstructive pulmonary disease

KW - β-agonist

UR - http://www.scopus.com/inward/record.url?scp=0030690212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030690212&partnerID=8YFLogxK

M3 - Article

VL - 2

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - SUPPL. 1

ER -